{
    "nct_id": "NCT05423197",
    "official_title": "Phase II Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma",
    "inclusion_criteria": "* Age ≥ 19 years.\n* Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.\n* Subjects diagnosed with any T stage, any subsite within the head and neck. Subjects with recurrent disease or a new primary will be allowed.\n* Must have standard of care 18F-FDG-PET/CT scan ≤ 30 days of Day 0 with suspected metastatic lesions.\n* Have acceptable hematological status, coagulation status, kidney function, and liver function including the following clinical results:\n\n  * Hemoglobin ≥ 9gm/dL\n  * White blood cell count > 3000/mm3\n  * Platelet count ≥ 100,000/mm3\n  * Serum creatinine ≤ 1.5 times upper reference range\n  * PTT = 11.5 - 14.4 seconds\n  * INR = 0.9 - 1.2\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
    "exclusion_criteria": "* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment\n* History of infusion reactions to other monoclonal antibody therapies\n* Pregnant or breastfeeding\n* Magnesium or potassium lower than the normal institutional values\n* Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents\n* Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis\n* Severe renal disease or anuria\n* Known hypersensitivity to deferoxamine or any of its components",
    "miscellaneous_criteria": ""
}